Algernon Pharmaceuticals Inc (AGNPF)

[boogawooga102]

Phase 2 Proof of Concept Study Topline Data Out This Month

Hearing some chatter in some private investor groups about their June 13th news release where they clearly announced topline data will be available in July. Could be a major catalyst for re-rating of the stock especially off these low prices.


VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that its Phase 2 proof-of-concept study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough has reached database lock. This means that all data from the trial is now finally reported, cleaned and “locked” in the database. As previously stated, the Company is projecting that topline data will be available in July, 2022.

https://financialpost.com/globe-newswire/algernon-pharmaceuticals-announces-database-lock-in-phase-2-study-of-ipf-and-chronic-cough